<?xml version="1.0" encoding="UTF-8"?>
<p>In the context of dengue these factors are complex, and although still not fully understood, mean that interventions must be specifically tailored to not only be effective against all four serotypes but to avoid detrimental enhancement effects in subsequent DENV infections or based on previous infections. Once such example of this is the Sanofi antibody-based vaccine which showed limited efficacy and elicited ADE in some trial participants [
 <xref rid="B19-vaccines-07-00203" ref-type="bibr">19</xref>].
</p>
